PerkinElmer, Waltham, Mass., and Boldon, UK-based Immunodiagnostic Systems Holdings (IDS) have reached an agreement whereby PerkinElmer will acquire IDS for approximately $155 million. The transaction has a total enterprise value of approximately $124 million and is expected to close early in the third quarter of 2021.
Through this acquisition, PerkinElmer aims to grow its overall diagnostics business and specifically its immunodiagnostics segment. Moreover, the deal will enable PerkinElmer to combine its channel expertise and testing capabilities with IDS’s chemiluminescence products in endocrinology, autoimmunity, and infectious diseases to better serve customers around the world.
IDS’s portfolio and expertise are expected to seamlessly integrate within EuroImmun, a PerkinElmer company since 2017. EuroImmun is a global leader in autoimmune testing and an emerging force in infectious disease, allergy, and molecular genetic testing.
“This proposed transaction is highly valuable for both parties as the respective product lines are to a large extent complementary,” says Wolfgang Schlumberger, CEO of EuroImmun. “The cooperation of our global distribution channels, the expansion of the immunoassay portfolio in closely related indication fields, and IDS’s fully automated random access chemiluminescence platform strengthen our presence in immunodiagnostics. Our customers will benefit from a broader range of assays and laboratory diagnostic workflows. We are excited about these new opportunities and we look forward to welcoming Immunodiagnostic Systems into the PerkinElmer family following the completion of the transaction.”
IDS is a leading in vitro diagnostic solution provider to the clinical laboratory market. The company develops, manufactures, and markets innovative immunoassays and automated immunoanalyzer technologies to provide improved diagnostic outcomes for patients. Its immunoassay portfolio is a combination of an endocrinology specialty testing menu and assay panels in complementary fields.